On Tuesday February 21, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q4 2022 year-end report (which will have been published earlier on February 21, at 07.30 CET). The presentation will be held in English. 

Dial-in number to the teleconference and a conference ID will be received by registering on the link below:
https://conference.financialhearings.com/teleconference/?id=5002757

The presentation will also be webcast and can be accessed from the following web address: 

https://ir.financialhearings.com/devyser-diagnostics-q4-2022

Speakers: CEO Fredrik Alpsten och CFO Sabina Berlin 

The information was submitted for publication, through the agency of the contact persons below, on February 14, 2023, at 11:00 CET.

For more information, please contact:

Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 67 3106

Sabina Berlin, CFO
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502

About Devyser Diagnostics AB (publ)

Devyser develops, produces, and sells genetic testing kits to laboratories in more than 50 countries. The products are used for advanced DNA testing in the hereditary disease, oncology, and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient monitoring. Devyser’s products simplify complex genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. The company was founded in 2004 and is based in Stockholm, Sweden.

Devyser’s shares are listed on the Nasdaq First North Growth Market Stockholm (ticker: DVYSR). The company’s Certified Adviser is Redeye AB. For more information, visit www.devyser.com.